collection
MENU ▼
Read by QxMD icon Read
search

STEMI

shared collection
6 papers 0 to 25 followers
By Alessandro Iadanza Interventional Cardiologist at Siena University Hospital
https://www.readbyqxmd.com/read/29029233/anticoagulation-combined-with-antiplatelet-therapy-in-patients-with-left-ventricular-thrombus-after-first-acute-myocardial-infarction
#1
Naoki Maniwa, Masashi Fujino, Michikazu Nakai, Kunihiro Nishimura, Yoshihiro Miyamoto, Yu Kataoka, Yasuhide Asaumi, Yoshio Tahara, Michio Nakanishi, Toshihisa Anzai, Kengo Kusano, Takashi Akasaka, Yoichi Goto, Teruo Noguchi, Satoshi Yasuda
Aims: There are limited data about the optimal anti-thrombotic therapy for preventing embolism while minimizing bleeding events in patients with first acute myocardial infarction (AMI) complicated by left ventricular thrombus (LVT). Methods and results: Among 2301 consecutive patients with AMI hospitalized between 2001 and 2014, we studied 1850 patients with first AMI who discharged alive to investigate clinical characteristics, incidence of systemic embolism (SE), and association between anticoagulation and embolic or bleeding events...
October 3, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28606950/pathophysiology-of-takotsubo-syndrome
#2
REVIEW
Francesco Pelliccia, Juan Carlos Kaski, Filippo Crea, Paolo G Camici
Originally described by Japanese authors in the 1990s, Takotsubo syndrome (TTS) generally presents as an acute myocardial infarction characterized by severe left ventricular dysfunction. TTS, however, differs from an acute coronary syndrome because patients have generally a normal coronary angiogram and left ventricular dysfunction, which extends beyond the territory subtended by a single coronary artery and recovers within days or weeks. The prognosis was initially thought to be benign, but subsequent studies have demonstrated that both short-term mortality and long-term mortality are higher than previously recognized...
June 13, 2017: Circulation
https://www.readbyqxmd.com/read/27502078/acute-myocardial-infarction
#3
REVIEW
Grant W Reed, Jeffrey E Rossi, Christopher P Cannon
Acute myocardial infarction has traditionally been divided into ST elevation or non-ST elevation myocardial infarction; however, therapies are similar between the two, and the overall management of acute myocardial infarction can be reviewed for simplicity. Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide, despite substantial improvements in prognosis over the past decade. The progress is a result of several major trends, including improvements in risk stratification, more widespread use of an invasive strategy, implementation of care delivery systems prioritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), advances in antiplatelet agents and anticoagulants, and greater use of secondary prevention strategies such as statins...
January 14, 2017: Lancet
https://www.readbyqxmd.com/read/23697515/mechanisms-of-acute-coronary-syndromes-and-their-implications-for-therapy
#4
REVIEW
Peter Libby
No abstract text is available yet for this article.
May 23, 2013: New England Journal of Medicine
https://www.readbyqxmd.com/read/25175921/prehospital-ticagrelor-in-st-segment-elevation-myocardial-infarction
#5
RANDOMIZED CONTROLLED TRIAL
Gilles Montalescot, Arnoud W van 't Hof, Frédéric Lapostolle, Johanne Silvain, Jens Flensted Lassen, Leonardo Bolognese, Warren J Cantor, Angel Cequier, Mohamed Chettibi, Shaun G Goodman, Christopher J Hammett, Kurt Huber, Magnus Janzon, Béla Merkely, Robert F Storey, Uwe Zeymer, Olivier Stibbe, Patrick Ecollan, Wim M J M Heutz, Eva Swahn, Jean-Philippe Collet, Frank F Willems, Caroline Baradat, Muriel Licour, Anne Tsatsaris, Eric Vicaut, Christian W Hamm
BACKGROUND: The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor can improve coronary reperfusion and the clinical outcome is unknown. METHODS: We conducted an international, multicenter, randomized, double-blind study involving 1862 patients with ongoing STEMI of less than 6 hours' duration, comparing prehospital (in the ambulance) versus in-hospital (in the catheterization laboratory) treatment with ticagrelor...
September 11, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/24009306/cochrane-corner-is-there-a-benefit-of-using-intracoronary-vasodilators-in-st-segment-elevation-myocardial-infarction
#6
EDITORIAL
Pascal Meier, Adam Timmis, Juan-Pablo Casas, Catherine Otto
No abstract text is available yet for this article.
October 2013: Heart: Official Journal of the British Cardiac Society
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"